Zygolide gives equine vets a new FDA-approved pergolide option

Dechra’s launch of Zygolide adds a new FDA-approved pergolide choice for horses with PPID at a time when equine practitioners are managing a growing population of senior horses. The company announced on January 5, 2026 that the FDA approved Zygolide as the first FDA-approved bioequivalent generic pergolide tablet for control of clinical signs associated with PPID in horses, and said the product would be available through veterinarians beginning in January. In parallel with the launch, Dechra also began running owner-facing promotional placements in The Horse that framed Zygolide around preserving the horse-owner bond, using lines such as “Rediscover the partnership with Zygolide” and “Help your horse feel their best so you can enjoy more happy moments together.” (dechra-us.com)

That matters because pergolide is already the standard medical therapy for PPID, but treatment can be a long, expensive, and compliance-sensitive process. PPID prevalence rises with age; Dechra cited estimates that about 21% of horses age 15 and older are affected, increasing to 30% in horses older than 30. In real-world practice, these horses often need lifelong medication, serial ACTH testing, and dose adjustments tied to both lab values and clinical response. The owner-directed launch messaging in The Horse suggests Dechra sees the emotional and practical burden of chronic PPID management as a key part of the market opportunity, not just the pharmacology. (dechra-us.com)

Zygolide itself is not a new active ingredient. It’s a 1 mg pergolide mesylate tablet approved under ANADA 200-823, which identifies it as an FDA-approved generic animal drug. According to the product labeling, it’s indicated for control of clinical signs associated with PPID, starts at 2 mcg/kg orally once daily, and should not exceed 4 mcg/kg daily. The tablets are half-scored, and the labeling says dosing should be adjusted to the nearest half-tablet and titrated to the lowest effective dose based on clinical signs and endocrine testing. The product is supplied in 60-count and 160-count cartons. (dechra-us.com)

Dechra is also emphasizing formulation and handling details that could matter in the barn aisle as much as in the exam room. The company says the tablets are peppermint flavored and designed with 360-degree scoring to support accurate dosing and more consistent daily administration. That speaks directly to a familiar challenge in PPID care: some horses resist pergolide, and dose escalation can be limited by appetite loss or lethargy, sometimes informally called the “pergolide veil.” Independent equine education sources note those effects are often temporary and may be managed by slower titration, which aligns with the Zygolide label’s recommendation to cut the dose by half for several days if intolerance develops, then titrate back up in 2 mcg/kg increments every two weeks. The company’s consumer-style ads in The Horse mirror that practical positioning by focusing less on novelty and more on helping horses feel better day to day. (dechra-us.com)

The approval package also gives clinicians a reminder of what to monitor. In the field study summarized in the label, 86 of 113 evaluable horses, or 76.1%, were considered treatment successes at day 180, and 47 of those 113 horses, or 41.6%, required a dose increase at day 90. Inappetence or decreased appetite occurred in 40 of 122 treated horses, lethargy was reported in 9.8%, and behavioral changes were also observed. Post-approval adverse event reporting for pergolide tablets has included anorexia, lethargy, weight loss, diarrhea or colic, laminitis, neurologic signs, and behavioral changes, though the label notes those reports cannot establish frequency or causality on their own. (dechra-us.com)

Why it matters: For veterinary teams, Zygolide’s arrival could modestly reshape PPID management by narrowing the gap between ideal therapy and what pet parents can sustain over time. Cost has been a persistent friction point in chronic pergolide therapy, especially for larger horses or those needing higher doses. Dechra explicitly framed Zygolide as a cost-relief option, and outside launch advertising in The Horse reinforced that point with a “cost-effective treatment” claim tied to Valley Vet pricing as of March 4, 2026. An FDA-approved generic may also be attractive where clinics and pet parents have relied on compounded pergolide for affordability, because it offers approved labeling, standardized manufacturing, and established bioequivalence. That said, clinicians will still need to individualize therapy, monitor ACTH and clinical signs, and set expectations that PPID control remains a long game rather than a one-tablet fix. (dechra-us.com)

There doesn’t appear to be much independent expert reaction published yet beyond company materials, promotional coverage, and advertising placements, which suggests the market is still in the early rollout phase. The practical questions now are whether Zygolide is stocked consistently, how its pharmacy pricing compares with brand and compounded alternatives, and whether its flavored, scored design actually improves adherence in the field. The tone of the early campaign in The Horse also suggests Dechra is trying to build owner recognition around quality of life and partnership, not just generic substitution. Those answers should emerge over the next few quarters as equine practitioners start switching, initiating, or re-titrating PPID cases on the product. (dechra-us.com)